Reimbursed Care Access in Tanzania

Currently classified as a strictly controlled substance under Tanzania's drug-control framework with no authorized medical use outside of approved clinical research. The Drug Control and Enforcement Act and successor instruments provide the legal basis for criminal penalties against unauthorized possession, supply or trafficking of psychotropic and hallucinogenic substances; Tanzania's Drug Control and Enforcement Authority (DCEA) enforces these controls. There is no public reimbursement pathway or routine clinical access for psilocybin in Tanzania. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Tanzania's domestic drug-control statutes and the DCEA criminalize unlicensed possession, manufacture and distribution of MDMA and related amphetamine-type psychotropics; there is no established medical reimbursement or licenced therapeutic program for MDMA-assisted therapy in Tanzania. # #.

Esketamine (the S‑enantiomer nasal product approved for treatment‑resistant depression in some high‑income jurisdictions) is not listed among routinely registered psychiatric medicines in public TMDA material and there is no published national reimbursement pathway or indication authorization for esketamine in Tanzania. Standard national regulatory oversight for marketing authorisation, imports and clinical trials is handled by the Tanzania Medicines and Medical Devices Authority (TMDA); absence of TMDA registration or public guidance means esketamine is effectively unavailable for routine clinical use or reimbursement. Where single‑patient or investigator‑led use were to be considered, TMDA authorisation and local ethics/clinical‑trial approval would be required. # #.

Ketamine is an established anesthetic and analgesic used in Tanzanian hospitals and emergency settings under standard medical regulation. Clinical use of ketamine for anesthesia and emergency sedation is described in peer‑reviewed literature from Tanzanian tertiary hospitals, indicating routine hospital access under standard medical practice and oversight by national regulators and health facilities. # #.

Regulatory and reimbursement context: ketamine as an injectable anesthetic is distributed through clinical supply chains regulated by TMDA (product registration, import control and pharmacovigilance) and may be procured by public hospitals and private facilities for procedural anesthesia and emergency care. There is no established, nationwide public reimbursement program in Tanzania that recognises ketamine as a reimbursable psychiatric treatment for depression (i.e., ketamine infusions for depression are not a nationally‑funded mental‑health benefit under published health insurance guidance), so any off‑label psychiatric use would be implemented at facility level and funded privately or via hospital budgets. For regulatory matters including medicine registration and clinical trial oversight, TMDA is the responsible national authority. # #.

Clinical-research and off‑label use: while ketamine is used clinically for anesthesia, formalised psychiatric ketamine programs (repeat IV infusion series for depression) and reimbursement frameworks common in some high‑income countries are not documented in Tanzania; any research studies would require TMDA and institutional ethics approval. The country’s drug‑control laws and DCEA focus enforcement on illicit diversion, and hospitals must maintain controlled‑drug supply and record‑keeping to avoid diversion. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National legislation criminalises unlicensed handling of psychotropic indolealkylamines such as DMT; there are no publicly available authorised medical or reimbursement pathways for DMT or DMT‑containing preparations in Tanzania. Any use outside tightly regulated, approved clinical trials would be unlawful. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Tanzania’s drug‑control framework does not provide for routine medical or reimbursed access to 5‑MeO‑DMT; handling is limited to authorised research (which would require TMDA and ethics approvals) or otherwise constitutes a criminal offence. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised clinical‑care or reimbursement pathway for ibogaine in Tanzania; possession, supply or administration outside of an authorised research protocol would be unlawful and subject to enforcement by DCEA. # #.

Although plant preparations such as ayahuasca are sometimes treated differently in some jurisdictions, Tanzania’s drug‑control framework controls the principal psychoactive constituents (DMT) and broadly criminalises unauthorised importation, possession and supply of psychotropic substances. Consequently, ayahuasca use, importation or distribution in Tanzania would fall within the scope of controlled‑substance offences absent an explicit national exemption or approved research permit. There is no documented authorised medical or reimbursed access for ayahuasca in Tanzania. # # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled in most national systems and Tanzania’s drug‑control law provides the legal basis to prohibit unauthorised possession or trafficking; there is no routine medical or reimbursed access in Tanzania. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines in the '2C‑' family are illegal to possess or supply without authorisation in Tanzania under broad psychotropic‑substance controls; there is no medical indication, clinical‑trial programme or reimbursement mechanism for 2C‑X compounds in Tanzania. # #.